Denali Therapeutics
San Francisco
About Denali Therapeutics
Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Total funding: $1.3B
- Funding stage: IPO
- Last round: Post-IPO Debt (Dec 2025)
- Ticker: nasdaq:DNLI
- Website: denalitherapeutics.com
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/denali-therapeutics-61977 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.